77 related articles for article (PubMed ID: 26234904)
1. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Kimura T; Toda N
Bioorg Med Chem; 2015 Sep; 23(17):5546-65. PubMed ID: 26234904
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
3. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.
Song F; Lu S; Gunnet J; Xu JZ; Wines P; Proost J; Liang Y; Baumann C; Lenhard J; Murray WV; Demarest KT; Kuo GH
J Med Chem; 2007 Jun; 50(12):2807-17. PubMed ID: 17500511
[TBL] [Abstract][Full Text] [Related]
8. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists.
Zhao X; Yoon DO; Yoo J; Park HJ
J Med Chem; 2021 Apr; 64(7):4130-4149. PubMed ID: 33769827
[TBL] [Abstract][Full Text] [Related]
9. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
10. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
[TBL] [Abstract][Full Text] [Related]
11. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel potent GPR40 full agonist.
Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells.
Yang M; Chisholm JW; Soelaiman S; Shryock JC
Mol Cell Endocrinol; 2010 Feb; 315(1-2):308-13. PubMed ID: 19815053
[TBL] [Abstract][Full Text] [Related]
14. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
[TBL] [Abstract][Full Text] [Related]
15. AMG 837: a potent, orally bioavailable GPR40 agonist.
Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC
Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
Kubo O; Takami K; Kamaura M; Watanabe K; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Kitazaki T; Murata T; Sato K
Bioorg Med Chem; 2021 Jul; 41():116208. PubMed ID: 34010766
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.
Pio B; Chobanian HR; Guo Y; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Ashley E; Orr R; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Samuel K; Chen Q; Shang J; Lamca J; Ehrhart J; Nargund R; Howard AD; Colletti SL
Bioorg Med Chem Lett; 2019 Jul; 29(14):1842-1848. PubMed ID: 31109791
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.
Yang L; Zhang J; Si L; Han L; Zhang B; Ma H; Xing J; Zhao L; Zhou J; Zhang H
Eur J Med Chem; 2016 Jun; 116():46-58. PubMed ID: 27054485
[TBL] [Abstract][Full Text] [Related]
19. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
[TBL] [Abstract][Full Text] [Related]
20. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]